<DOC>
	<DOCNO>NCT00730782</DOCNO>
	<brief_summary>The objective study evaluate safety candidate malaria vaccine ( PfAMA-1 ) 3 dos give monthly interval 2 different dosage AMA-1 ( 10 μg 50 μg ) adjuvanted either alum hydroxide AS02A Montanide ISA 720 healthy adult previously expose parasite Plasmodium falciparum .</brief_summary>
	<brief_title>Assessment Three Formulations Candidate Vaccine AMA 1 Healthy Dutch Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age &gt; 18 &lt; 45 year healthy volunteer . General good health base history clinical examination . All volunteer sign informed consent form . Negative pregnancy test . Use adequate contraception female three month third injection ( D140 ) . Reachable phone whole study period ( 18 month ) . History malaria residence malaria endemic area within past six month . Positive serology malaria antigen PfAMA1 Previously participate malaria vaccine study Symptoms , physical sign laboratory value suggestive systemic disorder , include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric condition , could interfere interpretation study result compromise health volunteer . Any laboratory abnormality screen blood sample beyond normal range , define UMC St Radboud . Positive HIV , HBV HCV test . Volunteers enrol clinical trial whole trial period . Volunteers receive chronic medication , especially immunosuppressive agent ( steroid , immunomodulating immunosuppressive drug ) three month precede screen visit study period . Pregnant lactating woman . Volunteers unable give write informed consent . Volunteers unable closely follow social , geographic psychological reason . Previous history drug alcohol abuse interfere normal social function period one year prior enrollment study . Volunteers perform exercise four hour blood draw donate blood non studyrelated purpose entire duration study . Known hypersensitivity vaccine component ( adjuvant peptide ) . Volunteers allow receive vaccination gammaglobulin period three month prior first immunization six month 3rd immunization . If vaccination necessary period , volunteer withdrawn study . Volunteers allow travel malaria endemic country study period .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>